| Neutering can help prevent prostate cancer | | Posted Friday, February 02, 2007 12:57:58 PM by Blog57 Team | | Several times in the past couple of months, I have had to do what no doctor looks forward to - deliver the diagnosis of cancer. While the pets afflicted were different in age, breed and residence, they all possessed a common trait. Each was an un-neutered male dog suffering from prostate cancer. While the primary benefit of neutering, permanent prevention of breeding, is quite apparent and well talked about, other benefits of equal importance have taken a back seat or even been forgotten completely. Most everyone remembers Bob Barker telling his audience to remember to spay and neuter their pets, but few fully understand the true health benefits within his catch phrase. As in humans, the canine prostate and other tissues of the body are directly affected by the production and/or presence of testosterone and, to a lesser degree, other growth stimulating hormones.... | |
| |
| | | Faulty Gene Doubles Risk of Prostate Cancer | | Posted Sunday, November 05, 2006 11:06:59 AM by Blog57 Team | | THURSDAY, Nov. 2 (HealthDay News) -- Men who are missing sections of the CHEK2 kinase gene -- which programs production of a chemical that alerts the body to DNA damage -- are nearly twice as likely to develop prostate cancer as other men, a new study finds. Researchers assessed 2,000 Polish men who were diagnosed with prostate cancer between 1999 and 2005, and compared them to 5,500 healthy people. The missing sections (exons 9 and 10) were noted in 15 (0.8 percent) of the prostate cancer patients and in 24 (0.4 percent) of the healthy people. In addition, the researchers noted the missing sections of the gene in four of the 249 men with a family history of prostate cancer. The study authors calculated that the deletion of these sections of the gene nearly doubles risk of prostate cancer in general, and quadruples the risk in men with a family history of the disease.... | |
| |
| | | Free prostate cancer screening Monday | | Posted Saturday, August 26, 2006 7:00:33 AM by Blog57 Team | | Free prostate cancer screenings will be offered to all men over the age of 40 (35 for African-American men and men with known family history of prostate cancer or undetermined family history) for 12 days in Kentucky from Aug. 19-31.These guidelines have been established by the Kentucky Prostate Cancer Coalition and the National Alliance of State Prostate Cancer Coalitions. Men are urged to be screened annually, take responsibility to establish their baseline PSAs early and monitor the changes in their PSA levels annually.The closest one to Logan County will be Tuesday, August 29 from 9 a.m.-1 p.m. at the Wal-Mart located at 150 Walton Ave. Call 800-657-3145 An appointment is preferred, but not necessarySeptember is National Prostate Cancer Awareness Month. Dr. Steve Henry has submitted a request for Kentucky to make a proclamation that September 2006 be named Prostate Cancer Awareness Month in our Commonwealth.One in six men will be diagnosed with prostate cancer compared to one in eight women being diagnosed with breast cancer.... | |
| |
| | | Biomira Stimuvax prostate cancer study results published | | Posted Monday, July 24, 2006 8:58:11 PM by Blog57 Team | | Biomira Inc. has announced publication of study results showing that Stimuvax, formerly known as BLP25 Liposome Vaccine or L-BLP25, could slow rising Prostate Specific Antigen (PSA) levels in some post-surgical prostate cancer patients, potentially delaying the need for initiation of androgen deprivation therapy (ADT). The study results were described in an article entitled "A Pilot Study of the Liposomal MUC1 vaccine BLP25 in Prostate Specific Antigen Failures After Radical Prostatectomy" that appears in the July 2006 issue of the Journal of Urology. PSA is a tumour marker used by physicians to detect prostate cancer, monitor treatment effects and guide medical management of men with this disease, rising levels being predictive of relapse and disease progression. The open-label phase 2 safety and efficacy trial, conducted at the Cross Cancer Institute in Edmonton, Alberta, enrolled 16 post-radical prostatectomy patients.... | |
| |
| |
|
|
